Risk factors
Recursion Pharmaceuticals (RXRX) risk factors
Item 1A of every Recursion Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors101 risks8 new6 dropped11 reworded
Recursion Pharmaceuticals added risks covering a June 2025 cost reduction plan, workforce cuts, and specific drug patent protections. Intellectual property uncertainty and ESG compliance also feature prominently among new disclosures.
Filed Feb 25, 2026 - FY2024 10-K risk factors99 risks
Clinical-stage biotechnology company with no approved products, $1.4 billion accumulated deficit, and reliance on unproven AI-driven drug discovery platforms.
Filed Feb 28, 2025